Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave more evidence for their effectiveness.
NICE does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) because its cost is too high in relation to its potential benefits in draft guidance out for consultation.